Science services company Thermo Fisher Scientific and Life Technologies Corporation have signed a definitive agreement under which Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share, or approximately $13.6 billion.
“We are extremely excited about this transaction because it creates the ultimate partner for our customers and significant value for our shareholders,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “The acquisition of Life Technologies enhances all three elements of our growth strategy: technological innovation, a unique customer value proposition and expansion in emerging markets.”
“Our customers in research and applied markets will now be able to achieve even higher levels of innovation and productivity by working with the combined company. We’re especially excited about the new opportunities we will have to leverage our complementary offerings, fueled by a shared commitment to continuous innovation. Together, we will be in an even stronger position to fulfill our company’s mission, which is to enable our customers to make the world healthier, cleaner and safer.”
“This transaction brings together two companies intent on accelerating innovation for our customers and achieving greater success in a highly competitive global industry,” said Gregory T. Lucier, chairman and chief executive officer of Life Technologies.
Life Technologies provides products and services to customers conducting scientific research and genetic analysis, as well as those in applied markets, such as forensics and food safety testing. Its offering includes a broad range of reagents, consumables, instruments and systems. Life’s technologies are protected by approximately 5,000 patents and licenses, and has more than 10,000 employees serving its customers around the world.
